JSPR - Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences | Benzinga
REDWOOD CITY, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that it will participate at the following upcoming medical and investor conferences in November:
American College of Allergy, Asthma, and Immunology (ACAAI) 2023 Annual Scientific Meeting
Conference Dates: November 9-13, 2023
Abstract Title: Briquilimab, an anti-CD117 antibody, prevents passive systemic anaphylaxis in mice expressing chimeric human/mouse CD117
Abstract ID: 8266
ePoster ID: P040
Category: Allergy Diagnostics and Immunotherapy
In-Person Presentation: 3:45-4:00 p.m. PST, November 10, 2023
Stifel Healthcare Conference
Conference Dates: November 14-15, 2023
Presentation: 1:50-2:20 p.m. EST, November 15, 2023
Evercore ISI HealthCONx Conference
Conference Dates: November 28-30, 2023
Presentation: 9:10-9:30 a.m. EST, November 29, 2023
Piper Sandler Healthcare Conference
Conference Dates: November 28-30, 2023
Presentation: 2:00-2:25 p.m. EST, November 30, 2023
Live webcasts of the Stifel, Evercore and Piper presentations will be available on the Events & News – Presentations page of the Company's Investor Relations website. An archived replay of each presentation will be available on the Company's website for 30 days following the live broadcast.
About Jasper
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a ...